Peter Serhan

Mr. Peter Serhan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
FAFiras Al-Hindawi
Firas Al-Hindawi
PSPeter Serhan
Peter Serhan
YGYonas E. Geda
Yonas E. Geda
FTFrancis Tsow
Francis Tsow
TWTeresa Wu
Teresa Wu
EFErica Forzani
Erica Forzani
Alzheimer’s disease (AD) represents a significant global health issue, affecting over 55 million individuals worldwide, with a progressive impact on cognitive and functional abilities. Early detection, particularly of mild cognitive impairment (MCI) as an indicator of potential AD onset, is crucial yet challenging, given the limitations of current diagnostic biomarkers and the need for non-invasive, accessible tools. This study aims to address these gaps by exploring driving performance as a novel, non-invasive biomarker for MCI detection. Using the LiveDrive AI system, equipped with multimodal sensing (MMS) technology and a driving performance assessment strategy, the proposed work analyzes the predictive capacity of driving patterns in indicating cognitive decline. Machine learning models, trained on an expert-annotated in-house dataset, were employed to detect MCI status from driving performance. Key findings demonstrate the feasibility of using nuanced driving features, such as velocity and acceleration during turning, as indicators of cognitive decline. This approach holds promise for integration into smartphone or car applications, enabling real-time, continuous cognitive health monitoring. The implications of this work suggest a transformative step towards scalable, real-world solutions for early AD diagnosis, with the potential to improve patient outcomes and disease management.

18 December 2024 in Sensors
Verified
Journal Article
Open access
PDF file
PSPeter Serhan
Peter Serhan
SVShaun Victor
Shaun Victor
OOOscar Osorio-Perez
Oscar Osorio-Perez
KKKevin Rabih Abi Karam
Kevin Rabih Abi Karam
AEAnthony Ziad Elghoul
Anthony Ziad Elghoul
EFErica Forzani
Erica Forzani
Alzheimer’s disease (AD) and Alzheimer’s Related Dementias (ADRD) are projected to affect 50 million people globally in the coming decades. Clinical research suggests that Mild Cognitive Impairment (MCI), a precursor to dementia, offers a critical window of opportunity for lifestyle interventions to delay or prevent the progression of AD/ADRD. Previous research indicates that lifestyle changes, including increased physical exercise, reduced caloric intake, and mentally stimulating activities, can reduce the risk of MCI. Early detection of MCI is challenging due to subtle and often unnoticed cognitive decline and is traditionally monitored through infrequent clinical tests. In this research, the Smart Driving System, a novel, unobtrusive, and economical technology to detect early stages of neurodegenerative diseases, is presented. The system comprises a multi-modal biosensing array (MMS) and AI algorithms, including driving performance and driver’s biometrics, offering insights into a driver’s cognitive function. This publication is the first work reported towards the ultimate goal of developing the Smart Driving Device and App, integrating it into vehicles, and validating its effectiveness in detecting MCI through comprehensive pilot studies.

28 January 2026 in Sensors
Verified
Journal Article
Open access
PDF file
PHPiyush Hota
Piyush Hota
APAdithya Shyamala Pandian
Adithya Shyamala Pandian
Rodrigo Ezequiel DominguezRodrigo Ezequiel Dominguez
Rodrigo Ezequiel Dominguez
MMManni Mo
Manni Mo
BFBo Fu
Bo Fu
EFErica Forzani
Erica Forzani
Acute kidney injury (AKI) affects thousands of hospitalized patients annually, yet early detection remains challenging as serum creatinine elevation lags behind clinical deterioration. Decreased urine output (UO) represents a key diagnostic criterion of AKI, sometimes manifesting hours before biochemical changes; however, current manual monitoring methods are labor-intensive and prone to error. Here, we developed and validated a simple, cost-effective automated urine flow meter using non-contact optical sensors, a peristaltic pump, and microcontroller-based automation for precise, real-time monitoring of urine output in clinical settings, named P-meter. Three successive prototypes (V1, V2, V3) were validated against gold-standard gravimetric measurements over 285 h of testing during animal experiments that required bladder catheterization. Iterative refinement addressed miniaturization challenges, fluid dynamics optimization, and sensor positioning to achieve progressively improved accuracy. The optimized V3 prototype demonstrated further enhanced volumetric precision, stability, and flow accuracy with near-unity linearity vs. reference method (R2 = 0.9889), minimal bias (mean error −0.1 mL), and 94.18% agreement within confidence limits (n = 86), outperforming the initial V1 prototype (R2 = 0.9971, mean error −1.69 mL, n = 207) and intermediate V2 design (R2 = 0.9941, mean error 3.63 mL, n = 390), primarily in terms of reduced bias and improved agreement. The P-meter offers accurate urine output monitoring at a lower cost than commercial systems, facilitating its use in early AKI detection and thereby improving patient outcomes.